{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T11:15:22Z","timestamp":1795259722684,"version":"4.10.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Major depressive disorder (MDD) is one of the most common mental disorders worldwide, estimated to affect 10\u201315% of the population per year. Treatment resistant depression (TRD) is estimated to affect a third of these patients who show difficulties in social and occupational function, decline of physical health, suicidal thoughts and increased health care utilization. We describe the prevalence of MDD, TRD and associated healthcare resource utilization in Maccabi Healthcare Services (MHS), a 2.5 million-member state-mandated health service in Israel.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All MHS members with an MDD diagnosis were identified within the years 2017\u20132018 and prevalence assessed by age, sex and TRD. To assess the incidence of MDD, members aged 18\u201365\u00a0years at the start of any MDD episode were identified between 1<jats:sup>st<\/jats:sup> January 2016 and 31<jats:sup>st<\/jats:sup> May 2018 with at least one systemic first-line antidepressant treatment within three months before or after the initial episode. Treatment patterns, time on first-line treatment, and healthcare resource utilization were compared by TRD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 4960 eligible MDD patients were identified (median age\u2009=\u200951\u00a0years, 65% female), representing a period prevalence of 0.218%, and of those, a high proportion of patients received drug treatment (92%). Among incident MDD cases (<jats:italic>n<\/jats:italic>\u2009=\u20092553), 24.4% had TRD. Factors associated with TRD included increasing age and personality disorder. Median time on treatment was 3.7\u00a0months (longer for those without TRD than those with) and 81.9% of patients purchased more than one month\u2019s supply of therapy. In the year after index, patients with TRD had a significant increased number of visits to primary care physicians, psychiatrists, emergency room visits, general hospitalizations, and psychiatric hospitalizations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study shows that prevalence of MDD in Israel is low compared to other countries, however once diagnosed, patients' are likely to receive drug treatment. Among patients diagnosed with MDD, the proportion of TRD is similar to other countries, increases with age and is associated with increased healthcare utilization, therefore should be a focus of continued research for finding effective long term treatment options.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04184-8","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T03:22:13Z","timestamp":1660188133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Epidemiology of treatment resistant depression among major depressive disorder patients in Israel"],"prefix":"10.1186","volume":"22","author":[{"given":"Sarah","family":"Sharman Moser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulamit","family":"Gelerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nava","family":"Barit Ben David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varda","family":"Shalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Stein-Reisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"4184_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"KS Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"4184_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1741-7015-9-90","volume":"9","author":"E Bromet","year":"2011","unstructured":"Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, De Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90.","journal-title":"BMC Med"},{"issue":"3","key":"4184_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3390\/jcm11030480","volume":"11","author":"P Ga\u0142ecki","year":"2022","unstructured":"Ga\u0142ecki P, Samochowiec J, Miku\u0142owska M, Szulc A. Treatment-Resistant Depression in Poland\u2014Epidemiology and Treatment. J Clin Med. 2022;11(3):480.","journal-title":"J Clin Med"},{"key":"4184_CR4","unstructured":"Organization WH. Depression and Other Common Mental Disorders [Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf;jsessionid=D1E4AA0966A230332D86ACB07CFE8150?sequence=1."},{"issue":"7","key":"4184_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/archgenpsychiatry.2009.36","volume":"66","author":"S Seedat","year":"2009","unstructured":"Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, et al. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry. 2009;66(7):785\u201395.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"4184_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0006-3223(03)00273-7","volume":"54","author":"WJ Katon","year":"2003","unstructured":"Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiat. 2003;54(3):216\u201326.","journal-title":"Biol Psychiat"},{"issue":"7","key":"4184_CR7","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","volume":"68","author":"D Souery","year":"2007","unstructured":"Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062\u201370.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"4184_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","volume":"9","author":"D Warden","year":"2007","unstructured":"Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR* D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449\u201359.","journal-title":"Curr Psychiatry Rep"},{"key":"4184_CR9","unstructured":"(APA) APA. Practice guidelines for the treatment of patients with major depressive disorder, 3rd edition. 2010 [Available from: http:\/\/psychiatryonline.org\/guidelines."},{"key":"4184_CR10","unstructured":"NICE. Depression in adults: recognition and management. Clinical Guideline CG90 2009 [Available from: https:\/\/www.nice.org.uk\/guidance\/cg90\/chapter\/1-Guidance."},{"issue":"2","key":"4184_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4088\/JCP.15m10381","volume":"78","author":"A Kautzky","year":"2017","unstructured":"Kautzky A, Baldinger-Melich P, Kranz GS, Vanicek T, Souery D, Montgomery S, et al. A New Prediction Model for Evaluating Treatment-Resistant Depression. J Clin Psychiatry. 2017;78(2):215\u201322.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"4184_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jad.2008.01.006","volume":"110","author":"D Amital","year":"2008","unstructured":"Amital D, Fostick L, Silberman A, Beckman M, Spivak B. Serious life events among resistant and non-resistant MDD patients. J Affect Disord. 2008;110(3):260\u20134.","journal-title":"J Affect Disord"},{"issue":"11","key":"4184_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4088\/JCP.v63n1102","volume":"63","author":"WH Crown","year":"2002","unstructured":"Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63(11):963\u201371.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"4184_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/070674370705200108","volume":"52","author":"MT Berlim","year":"2007","unstructured":"Berlim MT, Turecki G. Definition, assessment, and staging of treatment\u2014resistant refractory major depression: a review of current concepts and methods. The Canadian Journal of Psychiatry. 2007;52(1):46\u201354.","journal-title":"The Canadian Journal of Psychiatry"},{"issue":"8","key":"4184_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","volume":"53","author":"M Fava","year":"2003","unstructured":"Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiat. 2003;53(8):649\u201359.","journal-title":"Biol Psychiat"},{"key":"4184_CR16","unstructured":"Gaynes BN, Asher G, Gartlehner G, Hoffman V, Green J, Boland E, et al. AHRQ Technology Assessments. Definition of Treatment-Resistant Depression in the Medicare Population. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018."},{"issue":"1\u20132","key":"4184_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0924-977X(98)00004-2","volume":"9","author":"D Souery","year":"1999","unstructured":"Souery D, Amsterdam J, De Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1\u20132):83\u201391.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"4184_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/pr.117.014977","volume":"70","author":"F Caraci","year":"2018","unstructured":"Caraci F, Calabrese F, Molteni R, Bartova L, Dold M, Leggio GM, et al. International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. Pharmacol Rev. 2018;70(3):475\u2013504.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"4184_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0193-953X(05)70283-5","volume":"19","author":"M Fava","year":"1996","unstructured":"Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179\u2013200.","journal-title":"Psychiatr Clin North Am"},{"key":"4184_CR20","doi-asserted-by":"crossref","unstructured":"Souery D, Lipp O, Massat I, Mendlewicz J. The characterization and definition of treatment-resistant mood disorders. Treatment-resistant mood disorders Cambridge, UK. 2001:3\u201329.","DOI":"10.1017\/CBO9780511666421.002"},{"issue":"4","key":"4184_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/(SICI)1520-6394(1997)5:4<154::AID-DA2>3.0.CO;2-D","volume":"5","author":"RM Berman","year":"1997","unstructured":"Berman RM, Narasimhan M, Charney DS. Treatment-refractory depression: Definitions and characteristics. Depress Anxiety. 1997;5(4):154\u201364.","journal-title":"Depress Anxiety"},{"key":"4184_CR22","unstructured":"Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. The Journal of clinical psychiatry. 1997."},{"issue":"8","key":"4184_CR23","first-page":"17","volume":"68","author":"CB Nemeroff","year":"2007","unstructured":"Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(8):17.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"4184_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076882","volume":"8","author":"N Kubitz","year":"2013","unstructured":"Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS ONE. 2013;8(10): e76882.","journal-title":"PLoS ONE"},{"issue":"7","key":"4184_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/070674371405900702","volume":"59","author":"SJ Rizvi","year":"2014","unstructured":"Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, McIntyre RS, et al. Treatment-resistant depression in primary care across Canada. The Canadian Journal of Psychiatry. 2014;59(7):349\u201357.","journal-title":"The Canadian Journal of Psychiatry"},{"key":"4184_CR26","doi-asserted-by":"crossref","unstructured":"Dunner DL, Rush AJ, Russell JM, Burke M, Woodard S, Wingard P, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. The Journal of clinical psychiatry. 2006.","DOI":"10.4088\/JCP.v67n0501"},{"key":"4184_CR27","unstructured":"Cohen R. Membership in Sick Funds 2017 [Available from: https:\/\/www.btl.gov.il\/Publications\/survey\/Documents\/seker_303.pdf."},{"issue":"5","key":"4184_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/archpsyc.1994.03950050065007","volume":"51","author":"W Coryell","year":"1994","unstructured":"Coryell W, Akiskal HS, Leon AC, Winokur G, Maser JD, Mueller TI, et al. The time course of nonchronic major depressive disorder: Uniformity across episodes and samples. Arch Gen Psychiatry. 1994;51(5):405\u201310.","journal-title":"Arch Gen Psychiatry"},{"key":"4184_CR29","unstructured":"Israel Central Bureau of Statistics. Characterization and classification of geographic units by the soci-economic level of the population 2008. Publication No. 1530. Jerusalem, Israel; 2013 Report No.: Publication No. 1530 Contract No.: Publication No. 1530."},{"issue":"12","key":"4184_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1023\/B:EJEP.0000006635.36802.c8","volume":"18","author":"G Chodick","year":"2003","unstructured":"Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol. 2003;18(12):1143\u20136.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"4184_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/HYPERTENSIONAHA.114.03718","volume":"64","author":"D Weitzman","year":"2014","unstructured":"Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E. Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension. 2014;64(3):501\u20137.","journal-title":"Hypertension"},{"issue":"3","key":"4184_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijcard.2010.08.002","volume":"152","author":"V Shalev","year":"2011","unstructured":"Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol. 2011;152(3):345\u20139.","journal-title":"Int J Cardiol"},{"issue":"1","key":"4184_CR33","first-page":"59","volume":"4","author":"I Goldshtein","year":"2015","unstructured":"Goldshtein I, Chandler J, Shalev V, Ish-Shalom S, Nguyen A, Rouach V, et al. Osteoporosis in the community: findings from a novel computerized registry in a large health organization in Israel. J Aging Res Clin Pract. 2015;4(1):59\u201365.","journal-title":"J Aging Res Clin Pract"},{"key":"4184_CR34","unstructured":"Israel Center for Disease Control MoH. Israel National Cancer Registry 2019 [Available from: https:\/\/www.health.gov.il\/English\/MinistryUnits\/HealthDivision\/Icdc\/Icr\/Pages\/default.aspx."},{"issue":"6","key":"4184_CR35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"key":"4184_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1590\/1516-4446-2020-0650","volume":"42","author":"L Guti\u00e9rrez-Rojas","year":"2020","unstructured":"Guti\u00e9rrez-Rojas L, Porras-Segovia A, Dunne H, Andrade-Gonz\u00e1lez N, Cervilla JA. Prevalence and correlates of major depressive disorder: a systematic review. Brazilian Journal of Psychiatry. 2020;42:657\u201372.","journal-title":"Brazilian Journal of Psychiatry"},{"issue":"6","key":"4184_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/da.22230","volume":"31","author":"AJ Baxter","year":"2014","unstructured":"Baxter AJ, Scott KM, Ferrari AJ, Norman RE, Vos T, Whiteford HA. Challenging the myth of an \u201cepidemic\u201d of common mental disorders: trends in the global prevalence of anxiety and depression between 1990 and 2010. Depress Anxiety. 2014;31(6):506\u201316.","journal-title":"Depress Anxiety"},{"issue":"2","key":"4184_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4088\/JCP.14m09298","volume":"76","author":"PE Greenberg","year":"2015","unstructured":"Greenberg PE, Fournier A-A, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155\u201362.","journal-title":"J Clin Psychiatry"},{"key":"4184_CR39","unstructured":"Services SAaMHSAUDoHaH. National Survey of Drug Use and Health 2020 2020 [Available from: https:\/\/www.samhsa.gov\/data\/release\/2020-national-survey-drug-use-and-health-nsduh-releases."},{"issue":"23","key":"4184_CR40","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","volume":"289","author":"RC Kessler","year":"2003","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095\u2013105.","journal-title":"JAMA"},{"issue":"2","key":"4184_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1192\/bjp.bp.116.188078","volume":"210","author":"G Thornicroft","year":"2017","unstructured":"Thornicroft G, Chatterji S, Evans-Lacko S, Gruber M, Sampson N, Aguilar-Gaxiola S, et al. Undertreatment of people with major depressive disorder in 21 countries. The British journal of psychiatry\u202f: the journal of mental science. 2017;210(2):119\u201324.","journal-title":"The British journal of psychiatry : the journal of mental science"},{"issue":"8","key":"4184_CR42","first-page":"571","volume":"9","author":"G Geulayov","year":"2007","unstructured":"Geulayov G, Lipsitz J, Sabar R, Gross R. Depression in primary care in Israel. The Israel Medical Association journal\u202f: IMAJ. 2007;9(8):571\u20138.","journal-title":"The Israel Medical Association journal : IMAJ"},{"issue":"5","key":"4184_CR43","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1093\/geronb\/58.5.S305","volume":"58","author":"JM Wilmoth","year":"2003","unstructured":"Wilmoth JM, Chen P-C. Immigrant status, living arrangements, and depressive symptoms among middle-aged and older adults. J Gerontol B Psychol Sci Soc Sci. 2003;58(5):S305\u201313.","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"issue":"6","key":"4184_CR44","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0020764007082346","volume":"53","author":"A Tal","year":"2007","unstructured":"Tal A, Roe D, Corrigan PW. Mental illness stigma in the Israeli context: Deliberations and suggestions. Int J Soc Psychiatry. 2007;53(6):547\u201363.","journal-title":"Int J Soc Psychiatry"},{"key":"4184_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4088\/JCP.1106e16","volume":"67","author":"D Souery","year":"2006","unstructured":"Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67:16\u201322.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20132","key":"4184_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jad.2008.10.014","volume":"116","author":"A Fekadu","year":"2009","unstructured":"Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116(1\u20132):4\u201311.","journal-title":"J Affect Disord"},{"issue":"1","key":"4184_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40801-017-0126-5","volume":"5","author":"J Mahlich","year":"2018","unstructured":"Mahlich J, Tsukazawa S, Wiegand F. Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study. Drugs - Real World Outcomes. 2018;5(1):35\u201343.","journal-title":"Drugs - Real World Outcomes"},{"key":"4184_CR48","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jad.2013.12.011","volume":"156","author":"JJ Schuch","year":"2014","unstructured":"Schuch JJ, Roest AM, Nolen WA, Penninx BW, De Jonge P. Gender differences in major depressive disorder: results from the Netherlands study of depression and anxiety. J Affect Disord. 2014;156:156\u201363.","journal-title":"J Affect Disord"},{"issue":"5","key":"4184_CR49","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00406-002-0381-6","volume":"252","author":"J Angst","year":"2002","unstructured":"Angst J, Gamma A, Gastpar M, L\u00e9pine J-P, Mendlewicz J, Tylee A. Gender differences in depression. Eur Arch Psychiatry Clin Neurosci. 2002;252(5):201\u20139.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"4184_CR50","doi-asserted-by":"crossref","unstructured":"Van de Velde S, Bracke P, Levecque K. Gender differences in depression in 23 European countries. Cross-national variation in the gender gap in depression. Social science & medicine. 2010;71(2):305\u201313.","DOI":"10.1016\/j.socscimed.2010.03.035"},{"issue":"3","key":"4184_CR51","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1176\/appi.ajp.159.3.359","volume":"159","author":"RT Mulder","year":"2002","unstructured":"Mulder RT. Personality pathology and treatment outcome in major depression: a review. Am J Psychiatry. 2002;159(3):359\u201371.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"4184_CR52","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1521\/pedi.2006.20.4.307","volume":"20","author":"B Stanley","year":"2006","unstructured":"Stanley B, Wilson ST. Heightened subjective experience of depression in borderline personality disorder. J Pers Disord. 2006;20(4):307\u201318.","journal-title":"J Pers Disord"},{"issue":"2","key":"4184_CR53","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pnpbp.2009.12.021","volume":"34","author":"W He","year":"2010","unstructured":"He W, Chai H, Zheng L, Yu W, Chen W, Li J, et al. Mismatch negativity in treatment-resistant depression and borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):366\u201371.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4184_CR54","doi-asserted-by":"crossref","unstructured":"Takahashi M, Shirayama Y, Muneoka K, Suzuki M, Sato K, Hashimoto K. Personality traits as risk factors for treatment-resistant depression. PloS one. 2013;8(5):e63756-e.","DOI":"10.1371\/journal.pone.0063756"},{"issue":"8","key":"4184_CR55","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4088\/JCP.v65n0804","volume":"65","author":"JG Gunderson","year":"2004","unstructured":"Gunderson JG, Morey LC, Stout RL, Skodol AE, Shea MT, McGlashan TH, et al. Major depressive disorder and borderline personality disorder revisited: longitudinal interactions. J Clin Psychiatry. 2004;65(8):1049.","journal-title":"J Clin Psychiatry"},{"key":"4184_CR56","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.psychres.2016.04.034","volume":"240","author":"V De Carlo","year":"2016","unstructured":"De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response\/non-remission in treatment resistant depressed patients: a systematic review. Psychiatry Res. 2016;240:421\u201330.","journal-title":"Psychiatry Res"},{"issue":"9","key":"4184_CR57","first-page":"2059","volume":"58","author":"RJ Cadieux","year":"1998","unstructured":"Cadieux RJ. Practical management of treatment-resistant depression. Am Fam Physician. 1998;58(9):2059\u201362.","journal-title":"Am Fam Physician"},{"key":"4184_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4088\/JCP.v64n0301","volume":"64","author":"JC Nelson","year":"2003","unstructured":"Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry. 2003;64:5\u201312.","journal-title":"J Clin Psychiatry"},{"key":"4184_CR59","volume":"2011","author":"LM Mart\u00edn-L\u00f3pez","year":"2011","unstructured":"Mart\u00edn-L\u00f3pez LM, Rojo JE, Gibert K, Mart\u00edn JC, Sperry L, Du\u00f1\u00f3 L, et al. The strategy of combining antidepressants in the treatment of major depression: clinical experience in spanish outpatients. Depress Res Treat. 2011;2011: 140194.","journal-title":"Depress Res Treat"},{"issue":"11","key":"4184_CR60","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.8001tx13c","volume":"70","author":"M Fava","year":"2009","unstructured":"Fava M. Augmentation and combination strategies for complicated depression. J Clin Psychiatry. 2009;70(11): e40.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"4184_CR61","doi-asserted-by":"publisher","first-page":"191","DOI":"10.31887\/DCNS.2005.7.3\/dkupfer","volume":"7","author":"DJ Kupfer","year":"2005","unstructured":"Kupfer DJ. The pharmacological management of depression. Dialogues Clin Neurosci. 2005;7(3):191.","journal-title":"Dialogues Clin Neurosci"},{"issue":"4","key":"4184_CR62","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/00048670701881587","volume":"42","author":"GS Malhi","year":"2008","unstructured":"Malhi GS, Ng F, Berk M. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Aust N Z J Psychiatry. 2008;42(4):346\u20139.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"4184_CR63","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/0269881107065738","volume":"21","author":"N Hannan","year":"2007","unstructured":"Hannan N, Hamzah Z, Akinpeloye HO, Meagher D. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. Journal of psychopharmacology (Oxford, England). 2007;21(2):161\u20134.","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"issue":"11","key":"4184_CR64","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1742-1241.2012.03015.x","volume":"66","author":"D Saragoussi","year":"2012","unstructured":"Saragoussi D, Chollet J, Bineau S, Chalem Y, Milea D. Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) study. Int J Clin Pract. 2012;66(11):1079\u201387.","journal-title":"Int J Clin Pract"},{"issue":"6992","key":"4184_CR65","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1136\/bmj.310.6992.1433","volume":"310","author":"I Anderson","year":"1995","unstructured":"Anderson I, Tomenson B. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ\u202f: British Medical Journal. 1995;310(6992):1433\u20138.","journal-title":"BMJ : British Medical Journal"},{"key":"4184_CR66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jad.2018.06.045","volume":"242","author":"KM Johnston","year":"2019","unstructured":"Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195\u2013210.","journal-title":"J Affect Disord"},{"issue":"8","key":"4184_CR67","first-page":"e188","volume":"16","author":"C Centers","year":"2010","unstructured":"Centers C, Exchange P. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010;16(8):e188\u201396.","journal-title":"Am J Manag Care"},{"issue":"8","key":"4184_CR68","first-page":"814","volume":"26","author":"JF Steiner","year":"1988","unstructured":"Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation Med Care. 1988;26(8):814\u201323.","journal-title":"Description and validation Med Care"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04184-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T04:03:00Z","timestamp":1660190580000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04184-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4184"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04184-8","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"13 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state that they have obtained appropriate institutional review board approval and have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. The study was approved by the local ethics review board of Maccabi Healthcare Services in Israel who waived informed consent due to the anonymous retrospective nature of this database study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Shulamit Gellerstein and Nava Ben David were employees of Janssen Israel at the time of the study. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"541"}}